Sign inCreate account

Report workspace tools

NCT03140722TERMINATEDanonymous

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Indication / condition

AI-normalized

Anemia

Intervention

Source record

vadadustat, epoetin alfa

Source & freshness

Source record

NCT ID

NCT03140722

Original source

ClinicalTrials.gov

Source last updated

Feb 21, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03140722

Title

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Sponsor

Akebia Therapeutics

Status

TERMINATED

Phase

Phase 2

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Target normalized

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Interventions

vadadustat, epoetin alfa

Public preview

Source record

The trial evaluated vadadustat, an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor, against epoetin alfa for treating anemia in patients with DD-CKD who are hyporesponsive to erythropoiesis stimulating agents. The study was terminated due to a revised study design after enrolling only 2 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03140722

Status

TERMINATED

Phase

Phase 2

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

The trial evaluated vadadustat, an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor, against epoetin alfa for treating anemia in patients with DD-CKD who are hyporesponsive to erythropoiesis stimulating agents. The study was terminated due to a revised study design after enrolling only 2 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 21, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03140722

Indication

Anemia

Modality

small molecule

Target

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Intervention

vadadustat, epoetin alfa

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.